Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer by Zhou, Yanyan et al.
RESEARCH Open Access
Overexpressed HDGF as an independent
prognostic factor is involved in poor prognosis in
Chinese patients with liver cancer
Yanyan Zhou
1, Nanxiang Zhou
1, Weiyi Fang
2*, Jirong Huo
1*
Abstract
Background: Hepatoma-derived growth factor (HDGF) is involved in the hepatocarcinogenesis. In this study, we
investigated the HDGF expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic
features, including the survival of patients with HCC. Furthermore, we examined the biological processes regulated
by HDGF during the development of using HepG2 cell line as a model system.
Methods: we used immunohistochemistry to compare HDGF protein expression in HCC and normal liver tissues
and further analyze the HDGF protein expression in clinicopathologically characterized 137 HCC cases. We stably
knocked down the endogenous expression level of HDGF in HepG2 cells with specific shRNA-expressing lentiviral
vector. Following the successful establishment of stable cells, we examined in vitro cell growth by MTT assay,
anchorage-independent growth by soft-agar colony formation assay and cell migration/invasion by transwell and
boyden chamber assay. And in addition, we also investigated the in vivo tumor growth by xenograft
transplantation of HepG2 cells into nude mice.
Results: Protein expression level of HDGF was markedly higher in HCC tissues than that in the normal liver tissues
(P = 0.011). In addition, high expression of HDGF protein was positively correlated with T classification(p < 0.001), N
classification (p < 0.001), and clinical stage (p < 0.001) of HCC patients. Patients with higher HDGF expression
showed a significantly shorter overall survival time than did patients with low HDGF expression. Multivariate
analysis suggested that HDGF expression might be an independent prognostic indicator(p < 0.001) for the survival
of patients with HCC. HDGF-specific shRNA (shHDGF) successfully knocked down its endogenous expression in
HepG2 cells. Compared to the parental and control shRNA-transfected (shCtrl) HepG2 cells, the shHDGF cells
exhibited significantly reduced in vitro cell growth, anchorage-independent growth, cell migration and invasion (p
< 0.05). In vivo, the xenograft transplants from shHDGF cells gave rise to much smaller tumors as compared to
those from shCtrl cells.
Conclusion: High HDGF expression is associated with poor overall survival in patients with HCC. Down-regulation
of HDGF inhibits the growth, anchorage-independent growth, migration and invasion of HepG2 cells.
Background
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide, especially in Asia [1].
In China, HCC presents with the third highest mortality
rate among all malignant carcinomas, following gastric
and esophageal cancer, leading to approximately 110,000
deaths every year, which account for 45% of total HCC
deaths worldwide [2]. Multiple risk factors have been
associated with the initiation and development of HCC,
including chronic infection of hepatitis viruses B, C or
D, aflatoxin, alcohol abuse, hereditary metabolic liver
diseases, diabetes mellitus and etc [1,3]. Similar to most
other types of cancer, hepatocarcinogenesis is a multi-
step process involving multiple genetic alterations, such
as activation of oncogenes and inactivation of tumor
suppressor genes, which ultimately lead to malignant
transformation of hepatocytes.
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binding protein originally isolated from the conditioned
medium of HuH-7 hepatoma cell line [4,5]. Recent stu-
dies revealed that HDGF has mitogenic activity for mul-
tiple cell types, including HCC cells, fibroblasts,
endothelial cells, vascular smooth muscle cells and fetal
hepatocytes [4-8]. Besides, HDGF participates in other
cellular processes, such as renal development, cardiovas-
cular differentiation, angiogenesis and sensitization of
cancer cells to irradiation [9-12]. During cancer develop-
ment, high levels of HDGF were detected in various
human cancers[13], and its level has been demonstrated
as a prognostic factor for several cancers including gas-
tric [14], HCC [15], non-small-cell lung cancer [16,17],
esophageal carcinoma [18] and pancreatic cancer [19].
In order to clarify the role of HDGF in the pathogen-
esis of HCC, we investigated the correlation of HDGF
protein expression with clinicopathologic features with
HCC in Chinese populations. We found that the expres-
sion level of HDGF protein was higher in HCC tissues
than that in normal liver tissues. High expression of
HDGF was associated with poor prognosis of HCC.
Moreover, our results indicated that HDGF was involved
in progression of HCC by promoting cell growth, inva-
sion and migration of HCC cells. In our investigation,
HDGF may act as an oncogene in the pathogenesis of
HCC.
Materials and methods
Sample collecting
137 paraffin-embedded HCC samples and 49 noncancer-
ous paraffin-embedded normal liver samples were
obtained from People’sh o s p i t a lo fH u n a nP r o v i n c e ,
China. In 137 HCC cases, there were 87 male and
50 female ranging in age from 14 to 79 years (median,
48 years). For the use of these clinical materials for
research purposes, prior consents from the patients and
approval from the Ethics Committees of People’sh o s p i -
tal of Hunan Province were obtained and all the proce-
dures have been performed in compliance with the
Helsinki Declaration. All specimens had confirmed
pathological diagnosis and were staged according to the
2002 hepatocellular carcinomas staging system of the
International Union Against Cancer(UICC).
Immunohistochemistry (IHC)
Immunohistochemistry was performed according to
according to standard protocol[20-22] Paraffin sections
(3 μm) from 137 HCC samples and 49 normal liver
samples were deparaffinized in 100% xylene and re-
hydrated in descending ethanol series according to
standard protocols. Heat-induced antigen retrieval was
performed in 10 mM citrate buffer at 100°C for 2 min.
Endogenous peroxidase activity and non-specific antigen
were blocked with peroxidase blocking reagent contain-
ing 3% hydrogen peroxide and serum followed by incu-
bation with rabbit anti-human HDGF antibody (1:100,
Proteintech Inc,USA) overnight at 4°C. After washing,
the sections incubated with biotin-goat anti-mouse/rab-
bit antibody at room temperature for 10 minutes were
then conjugated with horseradish peroxidase (Maixin
Inc, China). The peroxidase reaction was developed with
3, 3-diaminobenzidine chromogen solution in DAB buf-
fer substrate. Sections were visualized with DAB and
counterstained with hematoxylin, mounted in neutral
gum and analyzed using a bright field microscope.
Evaluation of staining
The immunohistochemically-stained tissue sections were
reviewed and scored separately by two pathologists
blinded to the clinical parameters. HDGF expression in
the nucleus was independently evaluated. Cases in
which <90% and >90% of cancer cells at levels greater
than or equal to what is observed in the endothelial
cells were regarded as HDGF expression index (EI)
levels I and II, respectively[18,19]. HDGF EI was deter-
mined separately for the nucleus.
Cell line
The hepatoma cell line HepG2 was acquired from the
Cancer Institute, Central South University and cultured
in RPMI1640 medium (HyClone Inc, USA) supplemen-
ted with 10% fetal bovine serum (FBS) (PAA Labora-
tories, Inc, Austria) in a 37°C, 5% CO2 incubator.
Extraction of total RNA and reverse transcription followed
by PCR (RT-PCR)
Total RNA was extracted from approximately 1 × 10
6
cells using Trizol reagent (Invitrogen, USA) following
the manufacturer’s instructions. cDNA was then
s y n t h e s i z e df r o m2μmug total RNA using oligo(dT)15
as the primer along with the MMLV reverse transcrip-
tase (Takara Inc, Japan). To determine the steady-state
mRNA level of HDGF in HepG2 cells, PCR was per-
formed with the following primers: HDGF forward pri-
mer 5′-GAGGGTGACGGTGATAAGAA-3′,r e v e r s e
primer 5′-GAAACATTGGTGGCTACAGG-3′,a n dt h e
amplicon size is 377 bps. GAPDH (internal control)
forward primer 5′-TTCGCTCTCTGCTCCTC-3′,
reverse primer 5′-GATGATCTTGAGGCTGTTGT-3′,
and the amplicon size is 520 bps. The PCR condition
was one cycle of denaturation at 94°C for 2 min, 28
cycles of denaturation at 94°C for 20 seconds (s),
annealing at 55°C for 30 s and extension at 72°C for
30 s, followed by one cycle of final extension at 72°C
for 10 min. After the PCR reaction, the PCR products
was loaded on 1% agarose gel and visualized by ethi-
dium bromide staining.
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The BLOCK-iT RNAi lentiviral expression plasmid was
purchased from Invitrogen Inc. The shRNA sequence
targeting HDGF (shHDGF) and a control shRNA
sequence (shCtrl) targeting no known human genes was
d e s i g n e du s i n gt h eB L O C Ki TR N A iD e s i g n e rh t t p : / /
www.invitrogen.com as follows: shHDGF, sense 5′-
CACCGCCGTGAAATCAACAGCCAAAACGTTGG
CTGTTGATTTCACGG-3′;a n t i s e n s e5 ′-AAAACCGT-
GAAATCAACAGCCAACTTTTGGCTGTTGATTT-
CACGGC-3′.s h C t r l ,s e n s e5 ′-CACCGCCCTGAATT
GAACAGCCAAAACGTTGGCTGTTGATTTCACGG-
3′;5 ′-AAAACCGTGAAATCAACAGCCAACTTTTG
GCTGTTCAATTCAGGGC-3′. The shRNA primers
were cloned into the lentiviral expression plasmid fol-
lowing the manufacturer’s instruction and confirmed by
sequencing.
Establishment of HepG2 cell line stably expressing shRNA
shRNA-expressed lentiviral plasmid (either HDGF-speci-
fic or control) was transfected into HepG2 cells using
Lipofectamin2000 (Invitrogen) according to the Xie’s
instructions[23]. 48 h later, the cells were subjected to
Blasticidin selection at a final concentration of 1.2
μmug/mL. Following two weeks of selection, stable
pooled cells were further expanded for future
experiments.
Real-time PCR
Real-time PCR was performed to measure the knock
down efficiency of HDGF mRNA expression using
SYBR Premix Ex Taq (Takara, Japan) as described pre-
viously [22]. The sense primer: 5′ CAGCCAACAAA-
TACCAAGTCT 3′, Antisense primer: 5′ GTTCT
CGATCTCCCACAGC 3′. GAPDH gene was used as an
inner control. The sense primer: 5′ GAAGGTCGGAGT-
CAACGG 3′, Antisense primer: 5′ TGGAAGATGGT-
GATGGGATT 3′.
Western blot analysis
Approximately 5 × 10
6 cells were lysed in RIPA Buffer
(50 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 5 mM
DTT, 2% SDS) and total protein concentration deter-
mined with BCA assay (Beyotime Inc, China). 60 μmug
of total protein were loaded onto 10% SDS-PAGE gel.
Antibodies used for Western blot analysis included: rab-
bit polyclonal anti-HDGF antibody (Proteintech Inc,
1:200), anti-tubulin antibody (Santa Cruz, USA, 1:400),
and HRP-conjugated anti-rabbit secondary antibody
(Amersham Pharmacia Biotech, 1:50).
Cell growth analysis
Cell growth was determined by MTT assay (Sigma,
U S A ) .B r i e f l y ,1×1 0
3 cells were seeded into 96-well
plate with quadruplicate for each condition. 72 h later,
MTT reagent was added to each well at 5 mg/mL in 20
μmuL and incubated for another 4 h. The formazan
crystals formed by viable cells were then solubilized in
DMSO and measured at 490 nm for the absorbance (A)
values.
Soft agar colony formation assay
The anchorage-independent growth of hepatocytes was
monitored by the soft agar colony formation assay. In
brief, cells (100/well) resuspended in 1.5-ml mixture of
1.2% low-melt agarose and 2×RPMI 1640 (v:v = 1:1)
were loaded in triplicate on the top of the solidified bot-
tom agar comprising equal-volume mixture of 0.7% low-
melt agarose and RPMI 1640 in 12-well plates. The cells
were incubated at 37°C, 5% CO2 for two weeks. The
colonies composed of more than 50 Cells were counted.
In vitro migration and invasion assay
Cells growing in the log phase were treated with trypsin
and resuspended as single-cell solution. Then the cells
were counted and 1 × 10
5 cells in 1 mL of serum-free
RPMI 1640 medium were split into the upper chamber
of transwell and boyden chamber (8-μmum pore size,
BD Biosciences, USA) where the transwell membrane
was coated either with (for invasion) or without (for
migration) matrigel. Serum-free medium was also added
to the lower chamber. The migration assay proceeded in
37°C, 5%CO2 tissue culture incubator for 12 h and the
invasion assay, 18 h. The non-migrated/invaded cells in
the upper chamber were removed using cotton swap,
and the migrated/invaded cells fixed in methanol and
stained with eosin for migrated cells or Gimsa for
invaded cells. The cells trapped in or attached to the
reverse side of the porous membrane were photo-
graphed through × 200 microscope objective, the num-
bers of migrated cells in at least 5 random fields
counted under phase contrast microscope, and the aver-
age calculated.
In vivo xenograft tumor growth in nude mice
All animal protocols were approved by the Animal Care
and Use Committee of Central South University. Nude
mice between 4 to 6 weeks were purchased from the
Animal Center, Central South University (N = 5). 1 ×
10
6 cells growing in log phase were resuspended in
serum-free RPMI 1640 medium and injected subcuta-
neously into the 4-6 week-old male BALB/c nu/nu mice.
To minimize individual difference, shCtrl cells and
shHDGF cells were injected symmetrically to the left-
right flank of the same mouse. The mice were main-
tained in a barrier facility on HEPA-filtered racks. The
animals were fed with an autoclaved laboratory rodent
diet. All animal studies were conducted in accordance
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National Institutes of Health (NIH) Guide for the Care
and Use of Animals under assurance number A3873-1.
15 days later, the mice were sacrificed with tumors iso-
lated and their sizes and weights measured. Finally, the
HDGF expression was examined again by quantitative
real-time PCR in implanted nude mice of shRNA-
HDGF and control cell groups. GAPDH gene was used
as a normalizing control. The designed paired primers
were as follow, HDGF forward, 5′ CAGCCAACAAA-
TACCAAGTCT3′ reverse: 5′ GTTCTCGATCTCCCA-
CAGC 3′ GAPDHforward, 5′ GAAGGTCGGAGT
CAACGG 3′ reverse, 5′ TGGAAGATGGTGATGG-
GATT 3′. The PCR reaction was carried out in a
volume of 25 μl using SYBR Green Mix(Tiangen Inc,
China) on MXP3000 Instrument (Stratagene Labora-
tory). Experiments were repeated three times.
Statistical analysis
A l ld a t aw e r ea n a l y z e db yS P S S1 3 . 0s o f t w a r ea n dp r e -
sented as mean ± SD. The c
2 test was applied to analyze
the relationship between HDGF expression and clinico-
pathologic characteristics. Survival curves were plotted
by the Kaplan-Meier method and compared by the log-
rank test. The significance of various variables for survi-
val was analyzed by the Cox proportional hazards model
in the multivariate analysis. One-way ANOVA was
applied to test the differences between groups for all in
vitro analyses. ANOVA test was used for the in vivo
xenograft experiment. A P v a l u eo fl e s st h a n0 . 0 5w a s
considered statistically significant.
Results
Immunohistochemical analysis of HDGF protein
expression in HCC and normal liver tissues
We measured the expression level and subcellular locali-
zation of HDGF protein in 137 archived paraffin-
embedded HCC samples and 49 noncancerous samples
using immunohistochemical staining expression. Specific
HDGF staining was mainly founded in the nuclei and
cytoplasm of noncancerous and malignant epithelial
cells. We observed that 53.4% (73/137) archival HCC
biopsies showed HDGF EI levels 2 for the nuclei. In
comparison, the rate of EI levels 2 for HDGF protein
expression was 32.7%(16/49) in the nuclei of normal
epithelial cells(Figure 1A-D).
Correlation between HDGF expression and
clinicopathologic characteristics in Chinese HCC
We did not find a significant association of HDGF
expression in nuclei of tumor cells with age, gender,
HBV infection, smoking, drinking, T classification and
Figure 1 Detection of HDGF protein in HCC and Kaplan-Meier plots of overall survival duration in patients with HCC.H D G Fp r o t e i n
expression in HCC and normal liver samples. A and B. Strong expression of HDGF in HCC samples. C. Weak expression of HDGF in HCC samples
(original magnification 400×). D. Negative expression of HDGF in liver sample; E. Kaplan-Meier survival analysis of overall survival duration in 137
HCC patients according to HDGF protein expression. The log-rank test was used to calculate p values.
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Interestingly, we observed that the nuclear HDGF
expression was closely correlated with T classification (p
< 0.001), N classification (p < 0.001) and clinical stage
(p < 0.001) in patients with HCC(Table 1).
Survival analysis
To investigate the prognostic value of HDGF for HCC,
we assessed the association between HDGF expression
and survival duration using Kaplan-Meier analysis with
the log-rank test. The log-rank test showed that the
survival time of patients with HCC was significantly
different between the two groups with HDGF EI level
1a n d2( p < 0.001). In patients with HCC, the high
HDGF expression group had shorter survival, whereas
the low HDGF expression group had better survival
(Figure 1E).
In addition, N classification and clinical stage were
also significantly correlated with survival in Kaplan-
Meier analysis and log-rank test (for N classification,
p = 0.028; for clinical stage, p = 0.041). To determine
whether expression of HDGF is an independent prog-
nostic factor for HCC, we performed multivariate sur-
vival analysis of HDGF protein expression and factors
including with age, gender, smoking, drinking, HBV
infection, T classification, N classification, distant
metastasis, or clinical stage in patients with
HCC. The results showed that expression of HDGF
protein was an independent prognostic factor for
HCC (Table 2).
HDGF was highly expressed in HepG2 cells
To examine the biological functions of HDGF, we first
measured the expression level of endogenous HDGF in
HepG2 cells by RT-PCR. As shown in Figure 2A, when
the PCR cycle number was controlled (28 cycles) so that
both the HDGF and GAPDH products were in the lin-
ear range, HDGF showed an expression level compar-
able to that of the housekeeping gene GAPDH,
suggesting HDGF is highly expressed in HepG2 cells,
which also indicates that HepG2 is a good model system
for studying the functions of endogenous HDGF by loss-
of-function approach.
Endogenous HDGF was successfully knocked down by
shRNA-expressing lentiviral vector
To stably knock down the endogenous expression of
HDGF, we applied a lentiviral vector expressing specific
shRNA sequence targeting HDGF (shHDGF). As a con-
trol, we stably transfected the HepG2 cells with the
same lentiviral vector expressing a control shRNA
sequence (shCtrl) not targeting any known human
genes. By mRNA and protein expression analysis, we
found that the shCtrl cells have similar HDGF level as
the parental HepG2 cells, which were significantly
higher than that in the shHDGF cells (Figure 2B,C).
HDGF knockdown inhibited the growth of HepG2 cells
After successfully knocking down the endogenous
expression of HDGF, we first examined its effect on cell
growth. As shown in Figure 3, the parental HepG2 cells
had a similar growth rate as the shCtrl cells over a
seven-day period, while starting from day 3 the growth
of shHDGF cells were significantly slower than the for-
mer two cells (P < 0.05), suggesting HDGF promotes
the growth of HepG2 cells.
HDGF knockdown inhibited cellular transformation
We next explored the effect of HDGF on cellular
transformation. Since anchorage-independent growth is
a hallmark for transformed cells, we measured the
Table 1 Correlation between the clinicopathologic
characteristics and expression of HDGF protein in liver
cancer
Characteristics n HDGF (%) P
High expression Low expression
Group
Cancer tissue 137 73(53.3%) 64 (46.7%)
Normal tissue 49 16(32.7%) 33 (67.3%) 0.011
Gender
Male 87 51(58.6%) 36 (41.4%)
Female 50 22(44%) 28 (56%) 0.112
Age(y)
≥50 69 36 (52.2%) 33 (47.8%)
< 50 68 37(54.4%) 31(45.6%) 0.865
Smoking
Yes 47 24 (51.1%) 23 (48.9%)
No 90 49 (54.4%) 41 (45.6%) 0.722
Drinking wine
Yes 48 28(58.3%) 20(41.7%)
No 89 45(50.6%) 44(49.4%) 0.473
HBV Infection
Yes 103 54(52.4%) 49(47.6%)
No 34 19(55.9%) 15(44.1%) 0.843
T classification
T1-T2 98 42 (42.9%) 56(57.1%)
T3-T4 39 31 (79.5%) 8(20.5%) 0.000
N classification
N0-N1 64 22 (34.4%) 42 (65.6%)
N2-N3 73 51 (69.9%) 22 (30.1%) 0.000
Distant metastasis
Yes 33 22 (66.7%) 11 (33.3%)
No 104 51 (49%) 53 (51%) 0.109
Clinical stage
I~II 56 11(19.6%) 45 (80.4%)
III~IV 81 62 (76.5%) 19(23.5%) 0.000
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Parameter Univariate analysis Multivariate analysis
P HR 95%CI P HR 95%CI
Age
≥ 50vs. < 50 years 0.321 1.219 0.825-1.801
Gender
Male vs. female 0.310 1.229 0.826-1.829
Smoking
Yes vs. No 0.784 1.059 0.701-1.601
Wine
Yes vs. No 0.468 0.861 0.574-1.291
HBV infection
Yes vs. No 0.866 1.040 0.661-1.634
T classification
T3-T42 vs. T1-T 0.390 1.202 0.790-1.828
N classification
N2–N3 vs. N0 μ-N1 0.028 1.557 1.048-2.314 0.267 0.722 0.406-1.283
M classification
M0 vs. M1 0.170 0.731 0.468-1.143
Clinical stage
III-IV vs.I-II 0.041 1.526 1.017-2.290 0.335 1.443 0.684-3.044
HDGF Expression Index(EI)
II vs.I 0.000 2.316 1.548-3.464 0.000 0.358 0.210-0.610
HR: hazard ratio; CI: confidence interval
Figure 2 HDGF was highly expressed in HepG2 cells and this level was successfully knocked down by shRNA.A .T o t a lR N Aw a s
extracted from HepG2 cells and RT-PCR was applied to examine the steady-state mRNA levels of HDGF and GAPDH. B and C. Parental HepG2
cells and those stably transfected with either control (shCtrl) or HDGF-specific (shHDGF) shRNA were examined for HDGF expression by
quantitative real-time PCR and Western-blot. GAPDH and a-tubulin were used as internal control, respectively.
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HepG2 cells and the shCtrl cells formed similar num-
ber of colonies on soft agar over a two-week period
[(35.3 ± 3.5) vs. (36.7 ± 3.5)]. In contrast, knocking
down endogenous HDGF dramatically reduced the
number of colonies (9.3 ± 2.0)(p < 0.05), implying an
essential role of HDGF in regulating cellular transfor-
mation (Figure 4).
HDGF knockdown reduced cell migration and invasion
Cell migration and invasion are integral steps for the
process of tumor development and metastasis. When
testing the abilities of HepG2 cells to migrate/invade
through 8-μmum pores on the polycarbonate membrane
either without or with pre-coated matrigel, we found
the knocking down endogenous HDGF significantly
reduced the potentials of HepG2 cells to both migrate
and invade (p < 0.05), as compared to the parental or
shCtrl cells (Figure 5).
HDGF contributes to in vivo xenograft tumor growth
In addition to examining the biological functions of
HDGF in vitro, we also assessed the in vivo function of
HDGF using a xenograft transplantation model. By sub-
cutaneously transplanting the shCtrl or shHDGF cells
into nude mice, we monitored the tumor growth over a
15-day period. As shown in Figure 6, by measuring the
tumor weights, we found that shHDGF cells gave rise to
significantly smaller tumors than shCtrl cells (p <0 . 0 5 ) .
R e a l - t i m eq P C Rs h o w e dt h a tH D G Fe x p r e s s i o nw a s
obviously reduced in implanted nude mice of shHDGF
cell groups compared with control cell groups(Figure
6C).
Discussion
Hepatocellular carcinoma (HCC) is one of the most
common malignancies with extreme poor prognosis. It
was reported that in patients with symptomatic HCC,
the five-year survival rate is less than 5% [1]. On the
molecular level, a number of epigenetic and genetic
events have been associated with the development of
HCC, including inactivation of tumor suppressor p53
and epigenetic targeting of cancer-related genes such as
HIA-2, CDKN2A, p16-INK4a, E-cadherin and T-cad-
herin, activation of JNK1, ErbB-2, Wnt signaling and
multiple receptor tyrosine kinases[24-31]. All these
genetic and epigenetic alterations are not unique for
HCC, but also present in many other human malignan-
cies. Among the various changes, the up-regulation of
hepatoma-derived growth factor (HDGF) is gaining
increasing attentions. HDGF was first cloned from the
conditioned medium of hepatoma cell line HuH-7 and
Figure 3 Down-regulation of HDGF inhibited cell growth.T h e
cell growth of parental HepG2 cells and their stable derivatives,
shCtrl and shHDGF, were examined by MTT assay over a seven-day
period. *P < 0.05, as compared to parental HepG2 cells and shCtrl
cells.
Figure 4 Down-regulation of HDGF inhibited cell transformation. The anchorage-independent growth of parental HepG2 cells and their
stable derivatives, shCtrl and shHDGF, were examined by soft agar colony formation assay. A. Colonies were photographed. B. Bar graph
showed the differences of colony formation among the three groups. Data were presented as mean ± SD for three independent experiments.
*P < 0.05, as compared to parental HepG2 cells and shCtrl cells.
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parental HepG2 cells and their stable derivatives, shCtrl and shHDGF, were examined by transwell and boyden chamber assay. A and C.
Migrated or invaded cells were photographed under the microscope (200×). B and D. Quantifications of migration and invasion were presented
as mean ± SD for three independent experiments. *P < 0.05, as compared to parental HepG2 cells and shCtrl cells.
Figure 6 Down-regulation of HDGF inhibited in vivo xenograft tumor growth. A. shCtrl and shHDGF cells were injected subcutaneously
into nude mice (N = 5 for each group) and the tumors were isolated two weeks later. B. Tumor weights were quantified from 5 mice and
presented as mean ± SD. *P < 0.05, as compared to shCtrl cells.
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protein with mitogenic activity for fibroblasts [4].
Although initially identified as a secreted trophic factor,
recent evidence suggested that the nuclear targeting of
HDGF is essential for its mitogenic activity [32,33]. Con-
sistent with its function as a mitogen, HDGF is found to
be up-regulated in multiple cancers and its expression
level negatively correlates with the prognosis of cancer
patients including gastric cancer, HCC in Japan popula-
tions, non-small-cell lung cancer, esophageal carcinoma,
and pancreatic cancer [13-19], implying its importance
during cancer development. However, except for its
mitogenic activity, the expression role of HDGF in Chi-
nese population and the molecular understandings on
HDGF actions are quite limited, with most acquired
from gain-of-function studies [8,34,35]. In the present
study, we utilize immunohistochemistry to evaluate pro-
tein expression of HDGF in HCC and further analyze its
protein expression in clinicopathologically characterized
137 HCC cases.
HDGF protein was highly expressed in HCC tissues
compared with normal liver tissues. Subsequently, we
analyzed the correlation of HDGF expression with clini-
copathologic features in HCC. Inconsistent with Yoshi-
da’s report [15], our results indicated that significantly
increased nuclear protein expression of HDGF closely
associated with T classification (p < 0.001), N classifica-
tion (p < 0.001), clinical stage (p < 0.001) in patients
with HCC, which hinted that HDGF as a growth factor
might play an important role in HCC genesis and pro-
gression rather than distant metastasis(p = 0.109). The
discrepancy between our data and Yoshida’sd a t aw o u l d
be most likely due to the different samples and evalua-
tion criterion used for immunohistochemistry. Further-
more, we also found that the level of nuclear HDGF
protein expression was markedly correlated with overall
survival. In multivariate analyses, a high level of expres-
sion of HDGF protein was associated with a poor prog-
nosis for HCC. This result indicated that HDGF is a
potential unfavorable prognostic factor for Chinese
HCC patients. Similar to our result, Yoshida et al also
reported that HCC patients from Japan with a positive
HDGF index had significantly poorer disease-free and
overall survivals compared with patients with a negative
index [15].
Further, we analyzed the function of HDGF in HepG2
cells. By transfecting the cells with shRNA-expressing
lentiviral vector followed by selection with Blasticidin,
we successfully established stable cells expressing either
control or HDGF-specific shRNA, with the latter show-
ing dramatically reduced HDGF level as compared to
the former. The subsequent functional studies demon-
s t r a t e dt h a tk n o c k i n gd o w nt h ee n d o g e n o u se x p r e s s i o n
of HDGF led to significant reduced in vitro cell growth,
transformation, migration, invasion, as well as in vivo
xenograft tumor formation. Compared with the previous
gain-of-function studies, this loss-of-function study
offers more insights on the functions of endogenous
HDGF, minimizing the confounding factors that might
be introduced by overexpressed HDGF at a physiologi-
cally irrelevant high level. Our study also revealed a
n o v e lf u n c t i o no fH D G Fi nH C C ,t h a ti s ,t op r o m o t e
the cell migration and invasion, suggesting its potential
involvement in cancer metastasis. This is consistent
with the finding by Zhang et al. that down-regulation of
HDGF inhibits the invasion of non-small cell lung can-
cer cells [36], which further indicates that the biological
functions of HDGF are not unique to a specific cancer,
but common to multiple cancers. The observations that
HDGF regulates multiple cellular processes such as cell
growth, cell transformation, migration, invasion, and is a
prognostic factor for multiple cancers implies its impor-
tance as a therapeutic target for treating multiple
human cancers, including HCC. This is further sup-
ported by the recent work of Ren et al.t h a tp r o v i d e d
the experimental evidence of targeting HDGF as a strat-
egy for treating lung cancer [37].
Conclusion
In summary, we found that elevated expression of
nuclear protein expression of HDGF was not only
showed in HCC tissue compared with noncancerous
liver tissues, but also closely associated with T classifica-
tion, N classification, clinical stage in patients with
HCC. Furthermore, we also found that the level of
nuclear HDGF protein expression was significantly cor-
related with overall survival. In multivariate analyses, a
high level expression of nuclear HDGF protein was
associated with a poor prognosis for HCC. We applied
shRNA-mediated gene knockdown approach and exam-
ined the biological processes regulated by HDGF in
HepG2 cells. We demonstrated the functional impor-
tance of HDGF in cell growth, transformation, migration
and invasion, providing the directions for future studies
on molecular mechanisms of HDGF.
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